塞马格卢提德和癌症:一个系统的审查和元分析
Lakshmi Nagendra1, Harish Bg2, Meha Sharma3
1Department of Endocrinology, JSS Academy of Higher Education and Research, Mysore, India.
Diabetes & metabolic syndrome
|August 2, 2023
概括
与安慰剂或活性对照剂相比,包括在真实世界的研究中,塞马格卢提德的使用没有显示胰腺或甲状腺癌的风险增加. 这一发现得到了高级证据的支持,为患者和临床医生提供了有关癌症安全性的保证.
科学领域:
- 内分泌学 在内分泌学.
- 在瘤学瘤学.
- 药物监督 药物监督 药物监督
背景情况:
- 之前的研究将葡萄糖类-1受体激动剂 (GLP1RA) 与增加甲状腺癌风险联系起来.
- 以前没有关于赛马格卢提德与癌症风险相关的数据.
- 这项研究探讨了关于各种癌症的塞马格卢提德的安全性.
研究的目的:
- 系统地审查塞马格卢提德的安全性,重点关注癌症的发生.
- 为了评估与塞马格卢提德使用相关的胰腺和甲状腺癌的风险.
- 评估其他恶性瘤和严重不良事件的发生情况.
主要方法:
- 随机对照试验 (RCT) 和现实研究的系统审查.
- 在干预组中包括接受塞马格卢提德的患者.
- 主要结局:胰腺癌和甲状腺癌的发病率;次要结局:其他恶性瘤和严重不良事件.
主要成果:
- 分析了37个RCT和19个现实研究,涉及超过3万名患者.
- 塞马格卢提德的使用没有显著增加胰腺癌 (OR 0.25与安慰剂相比,P=0.21) 或甲状腺癌 (OR 2.04与安慰剂相比,P=0.44) 的风险.
- 与安慰剂 (OR 0.95,P=0.82) 或活性对照 (OR 0.91,P=0.79) 相比,没有观察到整体瘤的显著增加.
结论:
- 在RCT和现实世界的研究中,塞马格卢提德的使用与任何癌症类型的风险增加无关.
- 这些发现得到了大量证据的支持.
- 这一系统性审查提供了关于赛马格卢提德对癌症的安全性的可靠数据.
更多相关视频
10:28Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
Published on: January 22, 2018
11.2K
15:04Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
Published on: January 19, 2019
12.2K
相关概念视频
01:21Cancer Survival Analysis
384
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
384
02:56Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K